Algorithms and associated hardware that enhance the performance of existing cardiac devices (e.g., heart failure diagnosis, pacemaker ‘tuning’).
Aeglea BioTherapeutics is developing novel engineered human enzyme drug candidates that selectively target and inactivate amino acids required in tumorigenesis.
Preclinical-stage biopharmaceutical company developing small molecule therapeutics for cancer stem cells in the central nervous system for the treatment of glioblastoma multiforme (GBM) and other brain cancers.
Lumos Pharma is a biotechnology company dedicated to developing a treatment for Creatine Transporter Deficiency (CTD) patients and their families.
Developing treatments for niche, orphan drug indications for which there is no effective therapeutic option. First application: pleural disease.
Nanotechnology therapies that improve cancer treatment options for patients and physicians.